{
  "abstract": "Objective Although current treatment recommendations for systemic lupus erythematosus (SLE) provide the option for biologic agents without prior failure of immunosuppressants (IS), data on this treatment approach are limited. This study evaluates the efficacy and safety of anifrolumab by IS exposure.Methods Pooled data from the Phase 3 TULIP-1 ( NCT02446912) and TULIP-2 (NCT02446899) trials were analysed post hoc to compare patients with moderate-to-severe SLE treated with intravenous anifrolumab 300 mg or placebo alongside standard therapy by reported IS use. Efficacy outcomes by IS use included Definition of Remission in SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) attainment, analysed using a stratified Cochran–Mantel–Haenszel approach; all p values are nominal. Safety was summarised descriptively.Results In this analysis, 257 patients had no reported IS use (IS-inexperienced; anifrolumab 300 mg, n=127; placebo, n=130), and 469 were IS-experienced (anifrolumab 300 mg, n=233; placebo, n=236). At Week 52, DORIS remission and LLDAS attainment rates were higher with anifrolumab versus placebo in both IS subgroups (DORIS, IS-inexperienced, 16.2% vs 6.0%, p=0.0242; IS-experienced, 14.6% vs 7.3%, p=0.0304; LLDAS, IS-inexperienced, 34.0% vs 26.2%, p=0.1718; IS-experienced, 27.7% vs 16.2%, p=0.0038). Anifrolumab was well tolerated, regardless of reported IS history; safety was more favourable among IS-inexperienced versus IS-experienced patients.Conclusions This post hoc analysis of pooled TULIP-1/TULIP-2 data supports the efficacy and tolerability of anifrolumab in patients with moderate-to-severe SLE regardless of IS treatment history.",
  "authors": [
    {
      "affiliations": [
        "Rheumatology Unit, Department of Medicine, Padova University School of Medicine, Padova, Italy"
      ],
      "name": "Andrea Doria"
    },
    {
      "affiliations": [
        "Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"
      ],
      "name": "Ronald F van Vollenhoven"
    },
    {
      "affiliations": [
        "Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia"
      ],
      "name": "Eric F Morand"
    },
    {
      "affiliations": [
        "Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"
      ],
      "name": "Marta Mosca"
    },
    {
      "affiliations": [
        "BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"
      ],
      "name": "Jonatan Nåtman"
    },
    {
      "affiliations": [
        "BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"
      ],
      "name": "Miina Waratani"
    },
    {
      "affiliations": [
        "BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"
      ],
      "name": "Jacob Knagenhjelm"
    },
    {
      "affiliations": [
        "BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"
      ],
      "name": "Catharina Lindholm"
    },
    {
      "affiliations": [
        "BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"
      ],
      "name": "Danuta Kielar"
    }
  ],
  "title": "Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials",
  "uid": "d33a65ad-93a5-5ff5-a408-c8aaa401a592"
}